Natural Killer cell activation pathways (NK cell activation pathways)

Natural Killer (NK) cell activation pathways represent the integrated network of signaling events that determine the effector response of NK cells against infected or transformed cells. Unlike T cells, NK cell activation is governed by a complex 'rheostat' of germline-encoded activating receptors (such as NKG2D, CD16, and Natural Cytotoxicity Receptors like NKp30, NKp44, and NKp46) and inhibitory receptors (such as Killer-cell Immunoglobulin-like Receptors (KIRs) and NKG2A) (Lanier, LL. 2005, PMID: 15771571). When activating signals outweigh inhibitory ones—often due to the loss of Major Histocompatibility Complex (MHC) class I molecules or the upregulation of stress-induced ligands on target cells—NK cells execute cytotoxic functions through the release of perforin and granzymes and the secretion of pro-inflammatory cytokines like IFN-γ (Vivier E, et al. 2011, PMID: 21212348). In oncology, these pathways are targeted to overcome tumor-induced immunosuppression using checkpoint inhibitors like Monalizumab (targeting NKG2A) or through Antibody-Dependent Cellular Cytotoxicity (ADCC) mediated by CD16 (Shimasaki N, et al. 2020, PMID: 32024998). While highly promising for cancer immunotherapy, therapeutic manipulation of these pathways requires careful management to avoid systemic inflammatory responses or the breakdown of self-tolerance (André P, et al. 2018, PMID: 30550606).

Other names

NK cell signalingNatural Killer cell mediated cytotoxicityNK cell activationNK cell effector functions

Therapeutic modulation involves shifting the balance of signals toward activation by blocking inhibitory receptors (e.g., KIR, NKG2A), stimulating activating receptors (e.g., CD16 via ADCC), or providing pro-survival cytokine signals (e.g., IL-15).